Quick View
| Metric | Current Period | Same Period Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥234.33B | ¥202.65B | +15.6% |
| Operating Income | ¥24.73B | ¥20.74B | +19.2% |
| Profit Before Tax | ¥25.28B | ¥22.40B | +12.8% |
| Net Income | ¥19.15B | ¥15.34B | +24.9% |
| ROE | 2.1% | 1.7% | - |
Executive Summary
Revenue and profit increased in the quarter. Strong growth and improved profitability in overseas segments, including the Americas, EMEA, and China, drove higher earnings, while Operating Cash Flow temporarily turned negative due to an increase in working capital. Revenue was ¥234.33B (¥202.65B in the same period of the previous year, YoY +15.6%), Operating Income was ¥24.73B (¥20.74B, YoY +19.2%), and Net Income attributable to owners of the parent was ¥18.24B (¥14.47B, YoY +26.0%). The main drivers of revenue growth were strong growth in the Americas (YoY +22.3%), EMEA (+24.4%), and China (+16.6%). Combined with lower SG&A and R&D expense ratios, this improved the Operating Income margin to 10.6% (10.2% in the previous year). Profit Before Tax was ¥25.28B (¥22.40B in the previous year, YoY +12.8%), with higher finance costs somewhat offsetting the increase in Operating Income.
Factors Affecting Results
【Revenue】Revenue was ¥234.33B (YoY +15.6%). By region, the Americas was the largest and primary growth driver at ¥86.6B (37.0% of total, YoY +22.3%), followed by Japan at ¥57.9B (24.7% of total, +3.4%), China at ¥42.5B (18.2% of total, +16.6%), EMEA at ¥23.6B (10.1% of total, +24.4%), and East Asia and Global South at ¥20.2B (8.6% of total, +25.3%). While domestic growth was relatively moderate, overseas regions generally achieved double-digit growth, and the overseas revenue ratio continued to expand. Other businesses contracted to ¥3.4B (YoY -18.4%).
【Profit and Loss】Operating Income was ¥24.73B (YoY +19.2%), exceeding revenue growth, and the Operating Income margin improved to 10.6% (10.2% in the previous year). Although the gross margin declined by 0.8pt to 78.2% (79.0% in the previous year), the SG&A expense ratio decreased to 49.0% (49.4% in the previous year), while the R&D expense ratio also declined to 18.7% (19.1% in the previous year), with improved cost efficiency contributing to the higher margin. On a segment profit basis, the structure is such that ¥116.08B (¥95.35B in the previous year) from total reported segments, less R&D expenses of ¥38.88B and corporate administrative expenses and other costs of ¥53.72B (including ¥44.25B in profit-sharing payments for anticancer drugs), results in Operating Income of ¥24.73B. Profit Before Tax was ¥25.28B (¥22.40B in the previous year, YoY +12.8%), with finance costs more than doubling to ¥1.96B (¥0.92B in the previous year), partially offsetting profit growth. Net Income attributable to owners of the parent was ¥18.24B (YoY +26.0%), aided by a decline in the effective tax rate to 24.3% (31.6% in the previous year). Revenue and profit increased.
Segment Analysis
The Pharmaceutical Business consists of five regional segments: Japan, the Americas, China, EMEA, and East Asia/Global South. The Americas was the largest source of earnings, with revenue of ¥86.6B and segment profit of ¥51.9B (a 60.0% margin). Its increase in profit (+¥10.39B, YoY +25.0%) was also the largest among all segments. EMEA’s profit margin improved by +9.5pt to 52.7% (43.1% in the previous year), while profit growth of YoY +51.8% was the highest among all segments. China maintained a profit margin of 49.8%, the second-highest level after the Americas, and profit increased by YoY +18.2%. Japan recorded relatively moderate growth compared with other regions, with revenue up YoY +3.4% and profit up YoY +8.1%; its profit margin of 36.3% was also relatively low. East Asia and Global South continued to achieve strong revenue growth of YoY +25.3%, while the profit margin declined to 46.9% (51.1% in the previous year), indicating a slight slowdown in profit growth relative to revenue growth.
Key Financial Metrics
【Profitability】The Operating Income margin improved to 10.6% (10.2% in the previous year), while the Net Income margin, based on income attributable to owners of the parent, improved to 7.8% (7.1% in the previous year). ROE was 2.1% (based on quarterly results, before annualization). 【Cash Flow Quality】Operating Cash Flow was -¥2.59B, significantly below Net Income attributable to owners of the parent of ¥18.24B, indicating that the increase in working capital is weighing on cash generation. 【Investment Efficiency】Capital expenditures of ¥4.26B were approximately 0.45 times depreciation and amortization expense of ¥9.42B. This indicates a cautious investment stance during the quarter, while the R&D expense ratio of 18.7% demonstrates a continued level of R&D investment. 【Financial Soundness】The Equity Ratio declined slightly to 58.2% (62.0% in the previous year), reflecting an increase in interest-bearing debt. However, with a current ratio of approximately 2.24 times and cash and cash equivalents of ¥311.74B exceeding total interest-bearing debt of ¥271.34B, the Company remains in a net cash position and its financial base is generally sound.
Cash Flow Analysis
Operating Cash Flow was -¥2.59B (＋¥1.09B in the previous year). Despite recording Profit Before Tax of ¥25.28B, changes in working capital—accounts receivable +¥26.12B, inventories +¥24.46B, and accounts payable +¥11.64B—absorbed cash, causing OCF to turn negative. Investing Cash Flow was +¥6.46B (-¥9.37B in the previous year), mainly because proceeds of ¥10.91B from the sale and redemption of financial assets exceeded capital expenditures of ¥4.26B and other outflows. Financing Cash Flow was +¥57.92B (+¥26.09B in the previous year), as financing proceeds from a net increase in short-term borrowings of ¥34.01B and the issuance of bonds and ¥50.00B in long-term borrowings exceeded dividend payments of ¥22.57B. Free Cash Flow (Operating Cash Flow + Investing Cash Flow) was +¥3.87B, but fell short of dividend payments of ¥22.57B, with the shortfall funded through borrowings. As a result, cash and cash equivalents increased to ¥311.74B at quarter-end (¥245.42B at the end of the previous fiscal year), strengthening liquidity.
Quality of Earnings
The source of Operating Income was regional segment earnings from the Pharmaceutical Business. The impairment loss of ¥1.31B recorded in the same period of the previous year did not recur in the current period, and no material one-off gains or losses were identified. Below Operating Income, finance income of ¥2.51B and finance costs of ¥1.96B were recorded. Finance costs more than doubled from ¥0.92B in the previous year, reflecting an increase in borrowings. Comprehensive income was ¥31.18B (¥30.26B attributable to owners of the parent). The ¥12.02B difference from Net Income attributable to owners of the parent of ¥18.24B was mainly attributable to foreign currency translation adjustments for foreign operations of +¥14.38B, a foreign-exchange factor separate from business earnings. From an accruals perspective, OCF was below Net Income, and the accumulation of accounts receivable and inventories delayed the conversion of earnings into cash. Accordingly, the quality of earnings for the period was somewhat weak in terms of cash backing.
Earnings Outlook and Guidance
Progress against the full-year earnings forecasts was 26.5% for Revenue (¥234.33B/¥883.50B), 35.3% for Operating Income (¥24.73B/¥70.00B), and 34.9% for Net Income (¥18.24B attributable to owners of the parent/forecast of ¥52.30B). All exceeded the simple quarterly progress benchmark of 25%. The full-year forecasts incorporate substantial profit growth toward the second half of the fiscal year, with Operating Income forecast to increase YoY +58.6% and consolidated Net Income forecast to increase YoY +35.6%. The current quarter’s results—Operating Income YoY +19.2% and Net Income attributable to owners of the parent YoY +26.0%—represent growth ahead of these forecasts. As of the current quarter, no revisions had been made to the earnings or dividend forecasts.
Shareholder Returns
The full-year dividend forecast is ¥160 per share, representing a Payout Ratio of approximately 86.5% against forecast EPS of ¥185. Compared with the previous fiscal year’s actual dividend of ¥80 per share, the forecast dividend of ¥160 represents an increase. Dividend payments during the quarter were ¥22.57B (the same amount as in the previous year), while share repurchases were minimal at ¥0.002B, making dividends the main form of shareholder returns. Free Cash Flow of ¥3.87B during the quarter was below dividend payments, and recovery in OCF will be key to securing funding for shareholder returns over the full year.
Risk Factors
-
Temporary negative Operating Cash Flow due to an increase in working capital: Operating Cash Flow was -¥2.59B during the quarter, mainly due to increases of +¥26.12B in accounts receivable and +¥24.46B in inventories. The increase in accounts payable was limited to +¥11.64B and did not fully offset these outflows.
-
Decline in the gross margin due to foreign-exchange and product-mix fluctuations: The gross margin was 78.2%, down 0.8pt from 79.0% in the previous year. As the overseas revenue mix expands, including the Americas’ 37.0% share, sensitivity to foreign-exchange fluctuations may increase.
-
Increase in finance costs accompanying higher interest-bearing debt: Total interest-bearing debt increased to ¥271.34B (¥186.08B at the end of the same period of the previous year), while finance costs increased to ¥1.96B (¥0.92B in the previous year). The increase was driven by the issuance of bonds and ¥50.00B in long-term borrowings, as well as a net increase of ¥34.01B in short-term borrowings.
Industry Benchmark (For Reference; Compiled by the Company)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 10.6% | 17.5% (6.9%–23.1%) | −7.0pt |
| Net Income Margin | 8.2% | 7.0% (2.5%–15.6%) | +1.1pt |
The Operating Income margin is below the industry median, while the Net Income margin exceeds the median, indicating different industry positioning at the operating and bottom-line levels.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (Year-on-Year) | 15.6% | 9.8% (2.9%–13.0%) | +5.8pt |
The Revenue growth rate is significantly above the industry median and represents a high level of growth within the industry.
Source: Compiled by the Company
Key Earnings Highlights
-
In addition to the trend of higher revenue and profit, growth in highly profitable overseas segments such as the Americas, EMEA, and China drove an improvement in the Operating Income margin (10.2% in the previous year → 10.6%). The diversification of the regional portfolio represents a qualitative change in the earnings structure.
-
Full-year progress was 26.5% for Revenue, 35.3% for Operating Income, and 34.9% for Net Income, all exceeding the quarterly benchmark of 25%. The start toward achieving the full-year forecasts was favorable.
-
On the other hand, Operating Cash Flow was negative (-¥2.59B), creating a gap with Net Income attributable to owners of the parent of ¥18.24B. The primary cause was an increase in working capital, making cash-generation trends from the next quarter onward a key structural focus.
Theoretical Share Price (Reference Value)
This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade period). It is not a forecast of the market share price or a recommendation of any specific investment action.
| Scenario | Theoretical Share Price |
|---|---|
| bear (bearish) | ¥2,880 |
| base (base case) | ¥2,967 |
| bull (bullish) | ¥3,006 |
| Calculation Assumption | Value |
|---|---|
| Book Value per Share (BPS) | ¥3,216 |
| Adjusted Forecast EPS | ¥200.7 |
| Cost of Equity r | 9.15% (10-year Japanese government bond 2.65% + equity risk premium 6.00% + size premium 0.50%) |
| Residual Income Persistence Coefficient ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 86.5% |
| Forecast EPS Confidence Adjustment | ×1.085 (based on the track record of guidance achievement in the same industry) |
| Implied PBR / PER | 0.92x / 14.8x |
Sensitivity: ¥2,888–¥3,048 at ±1% for the cost of equity, and ¥2,959–¥2,972 at ±0.1 for ω.
Notes:
- Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
- Net assets as of the quarter-end are used (there is a timing difference relative to the full-year forecast).
(Calculation model: Residual Income Model / Interest rate reference month: 2026-06 / This value does not forecast or guarantee future share prices)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
Eisai delivered a strong FY2027 Q1 earnings result, with revenue growth, operating-profit growth and attributable-profit growth all exceeding the prior-year quarter. Revenue increased 15.6% YoY to ¥234.3bn. Operating income rose 19.2% to ¥24.7bn, lifting the operating margin by 31bp to 10.6%. Profit attributable to owners increased 26.0% to ¥18.2bn, and basic EPS rose to ¥64.71 from ¥51.35. Gross margin declined by approximately 80bp YoY to 78.2% because cost of sales increased faster than revenue. This gross-margin pressure was more than offset by modest operating-cost leverage, as SG&A rose 14.6% and R&D expense increased 12.7%, both below revenue growth. R&D spending remained substantial at ¥43.7bn, equal to 18.7% of revenue, which is consistent with an innovator-pharma business model. The Americas was the largest regional contributor to segment profit, generating ¥51.9bn, while revenue growth was broad-based across all pharmaceutical geographies. EMEA and East Asia/Global South posted the fastest revenue growth, although their smaller bases limit their absolute contribution. Segment profitability must be read together with the ¥44.3bn Lenvima profit-sharing payment to Merck & Co. included in headquarters and other costs, up ¥8.2bn YoY. This payment demonstrates the scale of Lenvima-related economics but also reduces the conversion of regional segment profits into consolidated operating income. Profit before tax grew a slower 12.8% than operating income because net finance income declined sharply as finance costs more than doubled. Net-income growth exceeded pre-tax-profit growth because the effective tax rate declined to 24.3% from approximately 31.5% in the prior-year quarter. Earnings cash conversion was weak: operating cash flow was negative ¥2.6bn despite ¥19.2bn of quarterly net income. The cash shortfall was principally associated with a ¥29.7bn working-capital outflow, alongside tax and interest payments. Liquidity remains adequate, with cash and equivalents of ¥311.7bn and a current ratio of 2.24x, but the quarter's cash increase was predominantly debt-funded. Q1 revenue reached 26.5% of full-year guidance and operating income reached 35.3%, placing operating-profit progress 10.3 percentage points above the standard 25% seasonal benchmark. Management maintained both earnings and dividend guidance, so the principal issues for subsequent quarters are the durability of overseas pharmaceutical growth, working-capital normalization, funding needs and conversion of first-quarter operating momentum into full-year cash earnings.
Profitability Analysis
The reported annualized ROE was 7.8%, below the 8% threshold generally associated with an adequate return profile for a mature pharmaceutical company. The annualized three-factor DuPont decomposition is 7.8% net profit margin × 0.602x asset turnover × 1.67x financial leverage, resulting in a 7.8% ROE. The main constraint on ROE is the 7.8% net margin, while asset turnover is modest because Eisai carries a large asset base including ¥263.2bn of goodwill, ¥85.6bn of intangible assets and ¥282.0bn of inventories. Financial leverage is moderate rather than excessive, and the 1.67x multiplier is not the primary source of shareholder returns. Revenue growth of 15.6% exceeded SG&A growth of 14.6% and R&D growth of 12.7%, producing favorable overhead and R&D leverage. Conversely, cost of sales rose 19.9%, faster than revenue, causing gross margin to contract to 78.2% from approximately 79.0%. The operating margin nevertheless improved to 10.6% from approximately 10.2%, as cost discipline below gross profit outweighed the gross-margin decline. The tax burden was normal at 0.722x, equivalent to a 24.3% effective tax rate. The interest burden of 1.022x indicates that finance income still exceeded finance costs, but the benefit narrowed materially: net finance income fell to ¥0.6bn from ¥1.7bn as finance costs rose to ¥2.0bn from ¥0.9bn. In regional reporting, the Americas is the core business by segment-profit contribution, with revenue of ¥86.6bn (+22.3% YoY) and segment profit of ¥51.9bn (+25.0% YoY), implying a 60.0% segment margin before centralized R&D and headquarters costs. Japan generated revenue of ¥57.9bn (+3.4%) and segment profit of ¥21.0bn (+8.1%), with a 36.3% segment margin. China generated revenue of ¥42.5bn (+16.6%) and segment profit of ¥21.2bn (+18.2%), with a 49.8% segment margin. EMEA generated revenue of ¥23.6bn (+24.4%) and segment profit of ¥12.5bn (+51.8%), with a 52.7% segment margin. East Asia and Global South generated revenue of ¥20.2bn (+25.3%) and segment profit of ¥9.5bn (+15.0%), with a 46.9% segment margin. Other businesses generated revenue of ¥3.4bn (-18.4%) and segment profit of ¥1.3bn (-44.0%). The sustainability of consolidated margin expansion depends on maintaining overseas growth and limiting the growth in collaboration-related, headquarters and financing costs.
Growth Assessment
Growth quality was favorable at the top line because all five pharmaceutical regional segments reported revenue expansion. The Americas added the largest absolute revenue increase, ¥15.8bn YoY, accounting for roughly half of consolidated revenue growth. China added ¥6.1bn, EMEA added ¥4.6bn and East Asia/Global South added ¥4.1bn, demonstrating broad international momentum. Japan was comparatively stable, with revenue up ¥1.9bn YoY. Consolidated operating income grew faster than revenue, confirming positive operating leverage despite the lower gross margin. However, profit before tax grew only 12.8%, lagging operating-income growth because the financing result weakened. The reduction in the effective tax rate supported reported net-income growth but is less indicative of underlying operating growth than the revenue and operating-income trends. R&D expenditure of ¥43.7bn represented an 18.7% R&D intensity, within the 15-20% range typical for innovator pharmaceutical companies and supportive of longer-term pipeline investment. Full-year guidance calls for revenue of ¥883.5bn, operating income of ¥70.0bn and attributable profit of ¥52.3bn. Q1 progress was 26.5% for revenue, 35.3% for operating income and 34.9% for attributable profit, versus a standard 25% first-quarter run rate. The operating-income progress rate is 10.3 percentage points above the seasonal benchmark, signaling a potentially front-loaded profit profile or a conservative full-year plan. No forecast revision was announced, making the next quarterly update important for determining whether the first-quarter earnings outperformance can be sustained.
Financial Health
Balance-sheet liquidity is sound. Current assets of ¥883.0bn exceeded current liabilities of ¥393.6bn, resulting in a current ratio of 2.24x and working capital of ¥489.4bn. Excluding inventories, the quick ratio was approximately 1.53x, also above the 1.0x healthy benchmark. Cash and equivalents increased ¥66.3bn during Q1 to ¥311.7bn. Total equity increased ¥8.0bn from the fiscal year-end to ¥933.2bn, while the equity ratio declined to 58.2% from 62.0% because liabilities grew faster than equity. The reported debt-to-equity ratio of 0.67x remains conservative relative to the 2.0x warning level. Nonetheless, bonds and borrowings increased by ¥85.3bn during the quarter, including a ¥35.4bn increase in short-term borrowings and ¥50.0bn of bond issuance and long-term borrowing proceeds. Short-term bonds and borrowings of ¥86.7bn are fully covered by cash and by current assets, limiting immediate maturity-mismatch risk. The incremental funding should nevertheless be monitored because it financed a period in which operating cash flow was negative and shareholder distributions remained material. Goodwill represented 28.2% of equity and 16.9% of total assets, remaining just below the 30% goodwill-to-equity threshold generally viewed as elevated. Intangible assets represented a further 5.5% of assets. The IFRS accounting framework does not amortize goodwill, so future impairment testing remains important if acquired or partnered assets underperform. Deferred tax assets totaled ¥107.8bn, equivalent to 11.5% of equity, making their recoverability dependent on sustained future taxable profitability.
Notable B/S Changes
Total assets: +¥108.98bn (+7.5%) versus FY-end, led by cash, receivables and inventories; the expansion was materially funded by additional borrowings. Cash and cash equivalents: +¥66.32bn (+27.0%) to ¥311.74bn - liquidity improved, although the increase was primarily supported by financing cash inflow. Inventories: +¥24.46bn (+9.5%) to ¥282.01bn - contributes to the 504-day DIO alert and elevates working-capital and potential obsolescence risk. Trade receivables: +¥26.12bn (+11.5%) to ¥253.13bn - contributes to 99-day DSO and weak Q1 cash conversion. Bonds and borrowings: +¥85.26bn (+45.8%) to ¥271.34bn - includes higher short-term borrowings and ¥50.0bn of new long-term funding; monitor use of proceeds and funding costs. Total liabilities: +¥100.93bn (+19.3%) to ¥624.92bn - increased substantially faster than equity, reducing the equity ratio to 58.2% from 62.0%. Goodwill: +¥3.95bn (+1.5%) to ¥263.15bn - remains 28.2% of equity; monitor impairment exposure under IFRS. Other components of equity: +¥14.35bn (+4.6%) to ¥325.42bn - primarily reflects favorable foreign-currency translation effects, partly offset by negative fair-value OCI.
Cash Flow Quality
Cash-flow quality is the key weakness in the quarter. Operating cash flow was negative ¥2.6bn against net income of ¥19.2bn, producing an OCF/net-income ratio of -0.14x, well below the 0.8x quality-warning threshold. The immediate root cause was a ¥29.7bn working-capital outflow, which more than offset pre-tax profit of ¥25.3bn and ¥9.4bn of depreciation and amortization. Trade receivables increased ¥26.1bn from the fiscal year-end to ¥253.1bn, while inventories increased ¥24.5bn to ¥282.0bn. The reported DSO of 99 days, DIO of 504 days and cash conversion cycle of 446 days are all materially above the stated warning thresholds. For a pharmaceutical company, elevated inventory can partly reflect manufacturing lead times, safety-stock requirements and product-launch preparation, but 504 inventory days materially tie up capital and elevate the risk of write-downs if demand, reimbursement or product mix changes. The 99-day receivables measure also requires monitoring for payment timing, channel inventory and collection discipline, particularly across international markets. The accruals ratio of 1.3% is low and does not independently indicate broad accrual inflation; nevertheless, the actual Q1 operating cash deficit means earnings have not converted into cash in the period. Reported free cash flow was positive ¥3.9bn, supported by a net investing cash inflow of ¥6.5bn, including ¥10.9bn of proceeds from sales and redemptions of financial assets. On a recurring operating-cash-flow-less-capex basis, cash generation was negative approximately ¥6.8bn after ¥4.3bn of capital expenditure, so the positive reported free cash flow should not be interpreted as fully recurring internally generated cash. Financing cash flow of ¥57.9bn, principally borrowings, was the dominant source of the quarter's cash increase. This financing dependence makes normalization of receivables and inventories important for assessing the quality and sustainability of future earnings.
Dividend Sustainability
The company maintained full-year DPS guidance of ¥160. Based on full-year EPS guidance of ¥185, the implied dividend payout ratio is approximately 86.5%, which is high but remains below 100%. Using shares outstanding net of treasury shares, the implied annual cash dividend is approximately ¥45.2bn, broadly consistent with the current quarterly dividend payment of ¥22.6bn representing a semiannual payment pattern. Q1 dividends paid of ¥22.6bn exceeded Q1 profit attributable to owners of ¥18.2bn, equivalent to a 123.7% quarterly payout ratio; this comparison is affected by the timing of semiannual dividend payments and should not be extrapolated mechanically. The dividend was not covered by Q1 operating cash flow, which was negative ¥2.6bn. Nor was it covered by recurring operating cash flow after capital expenditure, which was also negative for the quarter. The company had adequate cash reserves of ¥311.7bn and a healthy liquidity position to meet near-term distributions. However, the FY2027 payout profile leaves limited headroom if operating-income guidance, tax benefits or working-capital recovery fail to materialize. There was effectively no meaningful buyback activity in the quarter, so the relevant capital-return measure remains the dividend payout ratio rather than a total return ratio. Dividend sustainability therefore depends principally on delivery of the ¥52.3bn full-year attributable-profit forecast and recovery in operating cash conversion.
Risk Assessment
Business risks include Pharmaceutical revenue is increasingly dependent on international markets, particularly the Americas, which generated ¥86.6bn of Q1 revenue and ¥51.9bn of segment profit. Product demand, pricing, reimbursement, competitive launches and regulatory outcomes in overseas markets can therefore have a disproportionate impact., The ¥44.3bn Q1 Lenvima profit-sharing payment to Merck & Co., up 22.8% YoY, highlights a material collaboration-cost exposure. Changes in product sales, commercial terms or partnership economics could affect consolidated profit conversion., R&D expense of ¥43.7bn, or 18.7% of revenue, is strategically appropriate but inherently exposed to clinical-development failure, regulatory delay and uncertain returns on pipeline investment., High inventories, with DIO of 504 days, create industry-specific risks of demand forecasting error, expiry, obsolescence, manufacturing adjustment costs and inventory write-downs..
Financial risks include OCF/net income of -0.14x is a material earnings-quality alert. The negative operating cash flow reflects a ¥29.7bn working-capital outflow and reduces financial flexibility if it persists., DSO of 99 days and a 446-day cash conversion cycle indicate substantial capital tied up in receivables and inventories, increasing the risk that reported earnings lag cash realization., Bonds and borrowings increased by ¥85.3bn in Q1, while the equity ratio declined to 58.2% from 62.0%. The current D/E ratio is still moderate at 0.67x, but continued debt-funded cash generation would weaken the balance-sheet trajectory., Finance costs increased to ¥2.0bn from ¥0.9bn YoY, narrowing the net finance-income contribution and exposing pre-tax profit to higher funding costs., Goodwill of ¥263.2bn equals 28.2% of equity. While below the elevated threshold, IFRS goodwill is not amortized and could be subject to impairment if projected cash flows weaken..
Key concerns include Highest priority: normalize working capital and restore operating cash conversion; the combination of negative OCF, high DSO and exceptionally high DIO is the most immediate financial-quality concern., High priority: validate the sustainability of Q1 operating-profit progress, which was 35.3% of full-year guidance and 10.3 percentage points above the normal first-quarter pace., Medium-high priority: monitor borrowing growth and refinancing requirements after ¥85.3bn of incremental bonds and borrowings in Q1., Medium priority: assess whether gross-margin pressure persists, as cost of sales grew 19.9% versus revenue growth of 15.6%., Medium priority: monitor the effect of collaboration-related profit sharing, overseas pricing and clinical/regulatory developments on pharmaceutical profitability..
Investment Implications
Key takeaways include Q1 operating performance was strong: revenue grew 15.6%, operating income grew 19.2% and attributable profit grew 26.0% YoY., Operating-margin expansion to 10.6% was driven by SG&A and R&D leverage, despite an approximately 80bp decline in gross margin., The Americas remains the principal profit engine, while China, EMEA and East Asia/Global South supplied broad-based growth., Q1 operating cash flow was negative ¥2.6bn, making working-capital discipline the most important counterweight to the favorable earnings result., Full-year operating-income guidance appears conservative relative to Q1 progress, but maintenance of guidance indicates management has not yet confirmed an upgrade., Liquidity is strong and D/E is moderate, but the quarterly cash increase was financed mainly by new borrowings rather than operations., The implied FY dividend payout ratio of approximately 86.5% is high and relies on delivery of the full-year earnings and cash-flow plan..
Metrics to watch include Revenue growth and segment profit in the Americas, particularly the durability of the ¥86.6bn Q1 revenue base, Lenvima-related collaboration and profit-sharing costs, including the Merck payment, Gross margin following the Q1 decline to 78.2%, Operating cash flow relative to net income and the pace of working-capital release, Receivable days, inventory days and the cash conversion cycle, Short-term borrowings, bond issuance, finance costs and the equity ratio, Progress against full-year guidance: revenue ¥883.5bn, operating income ¥70.0bn, attributable profit ¥52.3bn and EPS ¥185, R&D intensity and clinical, regulatory and commercialization developments affecting the pharmaceutical pipeline.
Regarding relative positioning, Eisai shows an innovator-pharma profile with high gross margins, R&D intensity of 18.7% and meaningful international earnings contribution. Its annualized ROE of 7.8% is below stronger pharmaceutical-return benchmarks, while its 10.6% operating margin is within the good 8-15% range. The balance sheet is more resilient than that of highly leveraged peers, but cash conversion and unusually elevated inventory intensity currently represent weaker features relative to high-quality pharmaceutical cash generators.